Catalent, Inc. - stock earnings
CTLT Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| April 30, 2024 AfterMarket | - / 0.2048000000 | - | - / 1.1 billion | - |
CTLT Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -206.0 million USD | 1.0 billion USD |
| 2023Q3 | -86.0 million USD | 1.1 billion USD |
| 2023Q2 | -86.0 million USD | 1.1 billion USD |
| 2023Q1 | -227.0 million USD | 1.0 billion USD |
| 2022Q4 | 81.0 million USD | 1.1 billion USD |
| 2022Q3 | ? USD | 1.0 billion USD |
| 2022Q2 | 187.0 million USD | 1.3 billion USD |
| 2022Q1 | 141.0 million USD | 1.3 billion USD |
| 2021Q4 | 97.0 million USD | 1.2 billion USD |
| 2021Q3 | 93.0 million USD | 1.0 billion USD |
| 2021Q2 | 182.0 million USD | 1.2 billion USD |
| 2021Q1 | 231.8 million USD | 1.1 billion USD |
| 2020Q4 | 88.4 million USD | 910.8 million USD |
| 2020Q3 | 82.4 million USD | 845.7 million USD |
| 2020Q2 | 154.2 million USD | 947.6 million USD |
| 2020Q1 | 20.9 million USD | 760.6 million USD |
| 2019Q4 | 45.5 million USD | 721.4 million USD |
| 2019Q3 | 100000 USD | 664.7 million USD |
| 2019Q2 | 71.1 million USD | 725.7 million USD |
| 2019Q1 | 31.7 million USD | 617.5 million USD |
| 2018Q4 | 49.0 million USD | 623.0 million USD |
| 2018Q3 | -14.4 million USD | 551.8 million USD |
| 2018Q2 | 82.7 million USD | 685.3 million USD |
| 2018Q1 | 19.0 million USD | 627.9 million USD |
| 2017Q4 | -21.9 million USD | 606.3 million USD |
| 2017Q3 | 3.8 million USD | 543.9 million USD |
| 2017Q2 | 61.8 million USD | 616.9 million USD |
| 2017Q1 | 26.0 million USD | 532.6 million USD |
| 2016Q4 | 17.4 million USD | 483.7 million USD |
| 2016Q3 | 4.6 million USD | 442.2 million USD |
| 2016Q2 | 58.1 million USD | 532.2 million USD |
| 2016Q1 | 9.8 million USD | 438.0 million USD |
| 2015Q4 | 30.7 million USD | 454.9 million USD |
| 2015Q3 | 9.1 million USD | 423.0 million USD |
| 2015Q2 | 153.7 million USD | 510.1 million USD |
| 2015Q1 | 31.5 million USD | 446.6 million USD |
| 2014Q4 | 46.5 million USD | 455.8 million USD |
| 2014Q3 | -19.5 million USD | 418.3 million USD |
| 2014Q2 | 27.2 million USD | 519.6 million USD |
| 2014Q1 | 6.7 million USD | 453.1 million USD |
| 2013Q4 | -19.2 million USD | 440.7 million USD |
| 2013Q3 | 1.5 million USD | 414.3 million USD |
| 2013Q2 | 19.2 million USD | 505.2 million USD |
| 2013Q1 | -18.8 million USD | 447.0 million USD |
| 2012Q4 | -27.4 million USD | 436.1 million USD |
| 2012Q3 | -19.7 million USD | 412.0 million USD |
| 2012Q2 | ? USD | 1.7 billion USD |
CTLT Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -232.0 million USD | 4.3 billion USD |
| 2022 | 499.0 million USD | 4.8 billion USD |
| 2021 | 585.0 million USD | 4.0 billion USD |
| 2020 | 221.0 million USD | 3.1 billion USD |
| 2019 | 137.4 million USD | 2.5 billion USD |
| 2018 | 83.6 million USD | 2.5 billion USD |
| 2017 | 109.8 million USD | 2.1 billion USD |
| 2016 | 111.5 million USD | 1.8 billion USD |
| 2015 | 212.2 million USD | 1.8 billion USD |
| 2014 | 16.2 million USD | 1.8 billion USD |
| 2013 | -46.7 million USD | 1.8 billion USD |
| 2012 | -24.4 million USD | 1.7 billion USD |
| 2011 | -54.0 million USD | 1.5 billion USD |
CTLT
Price: $56.50
52 week price:
Earnings Per Share: -7.18 USD
P/E Ratio: -10.11
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 3.0 million
Ebitda: 115.6 millionMarket Capitalization: 10.1 billion